• Cytarabine (AraC): Mechanistic Insights and Innovations in A

  2026-05-11

  Explore how Cytarabine (AraC) drives apoptosis and DNA damage studies at a mechanistic level. This article uniquely bridges molecular actions with new insights from viral cell death regulation, empowering advanced leukemia and cell death research.

• CUDC-907: Technical Parameters for Dual PI3K and HDAC Inhibi

  2026-05-11

  CUDC-907 is a dual PI3K and HDAC inhibitor designed for controlled in vitro studies that require simultaneous modulation of PI3K/AKT signaling and histone deacetylase activity. It is optimized for cell-based oncology workflows but is not validated for diagnostic or therapeutic use.

• Comparative In Vitro Activity of Sisomicin and Tobramycin

  2026-05-10

  This study rigorously compared the in vitro efficacy of sisomicin, a novel aminoglycoside antibiotic, to established agents like tobramycin and gentamicin across over 560 clinical isolates. The findings clarify nuanced drug potency, resistance patterns, and experimental parameters vital for antibiotic selection and resistance research.

• EZH2 Inhibition Modulates SASP via cGAS-STING in SCLC Senesc

  2026-05-09

  This study demonstrates that inhibiting EZH2 mitigates the senescence-associated secretory phenotype (SASP) induced by the HDAC inhibitor SAHA in small cell lung cancer (SCLC) cells. The findings elucidate how nuclear pore protein Tpr and cytoplasmic chromatin fragments activate the cGAS-STING pathway, highlighting a novel axis for therapeutic intervention in SCLC.

• Quantitative In Vitro Evaluation of Drug Responses in Cancer

  2026-05-09

  Schwartz’s dissertation introduces a systematic approach to distinguish between drug-induced proliferative arrest and cell death in cancer cell lines, enhancing the precision of in vitro drug response assays. These findings have practical implications for optimizing anticancer screening workflows and understanding mechanisms of action.

• Integrated Genomics Reveal Immune Vulnerabilities in Mesothe

  2026-05-08

  This study applies integrated genomic profiling to uncover novel immune and cell cycle vulnerabilities in pleural mesothelioma, including frequent deletions in SUFU, RB1, and co-deletion of type I interferon and CDKN2A loci. These findings suggest new molecular targets for therapy and provide a refined map for future translational research in this aggressive cancer.

• Targeting AMPA/NMDA Receptors for Neuroprotection in Soman S

  2026-05-07

  The reference study demonstrates that dual glutamate receptor antagonism, specifically with IEM-1925, offers potent antiseizure, neuroprotective, and cognitive benefits in a rat model of soman-induced status epilepticus. These findings highlight a promising new strategy for managing organophosphorus nerve agent-induced neurotoxicity and suggest practical assay approaches for translational neuroprotection research.

• Capsaicin for Advanced TRPV1 and KDM1A Research Workflows

  2026-05-07

  Capsaicin ((E)-Capsaicin) is a dual-acting research tool enabling precision TRPV1 ion channel activation and potent KDM1A/LSD1 inhibition. Explore how APExBIO's Capsaicin powers robust pain, inflammation, and gastric cancer models—plus expert troubleshooting and workflow innovations.

• Ionizing Radiation Alters Neural Differentiation via PI3K-ST

  2026-05-06

  This study uncovers that ionizing radiation induces altered neuronal differentiation in C17.2 mouse neural stem-like cells via the PI3K-STAT3-mGluR1 pathway. These mechanistic insights highlight the complex impact of radiation on neurogenesis, with implications for radiotherapy side effects and neural epigenetic regulation.

• Bortezomib (PS-341): Precision Proteasome Inhibition for Can

  2026-05-06

  Bortezomib (PS-341) stands out as a reversible 20S proteasome inhibitor, enabling robust investigation of apoptosis and proteasome-regulated cellular processes in cancer models. This article unpacks advanced protocols, troubleshooting strategies, and key innovations that differentiate Bortezomib-driven workflows, with actionable guidance for multiple myeloma and pyrimidine metabolism research.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-05-05

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent protein degradation during extraction and analysis, especially where divalent cation-sensitive assays are required. It should be used in workflows needing broad-spectrum protease inhibition without EDTA, but is not suitable for protocols where DMSO is incompatible or in workflows not requiring protease inhibition.

• Bay 11-7821: Optimizing NF-κB Pathway & Inflammation Researc

  2026-05-05

  Bay 11-7821 (BAY 11-7082) delivers precise, reproducible inhibition of the NF-κB pathway, empowering researchers to dissect inflammatory signaling and apoptosis regulation with confidence. This guide translates recent bench breakthroughs and troubleshooting strategies into actionable laboratory protocols for inflammatory, cancer, and immune studies.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Techn

  2026-05-04

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) addresses the challenge of protein degradation during extraction and handling, particularly in workflows sensitive to divalent cations. It should be used for applications like Western blotting, co-immunoprecipitation, and kinase assays where broad-spectrum inhibition is needed, but is not intended for protocols requiring EDTA-mediated metalloprotease inhibition.

• RSL3: Glutathione Peroxidase 4 Inhibitor for Precision Ferro

  2026-05-04

  Unlock the power of (1S,3R)-RSL3—APExBIO’s potent glutathione peroxidase 4 inhibitor—for robust, selective ferroptosis induction in cancer research. This guide delivers actionable workflows, troubleshooting insights, and the latest translational breakthroughs to accelerate your oxidative stress and synthetic lethality assays.

• Substance P in Precision Bioassays: Innovations Beyond Pain

  2026-05-03

  Explore the multifaceted role of Substance P, a tachykinin neuropeptide, in high-precision bioassay design. Uncover advanced analytical strategies and new insights into assay interference, setting this article apart from conventional pain transmission research.

458 records 19/31 page Previous Next First page 上5页 1617181920 下5页 Last page